Individuals with COVID-19 in the ICU had two times longer acute brain dysfunction -- comatose or delirium -- compared with other ICU patients, with 82% having comatose for a median of 10 days and 55% having delirium for a median of three days, according to a study in The Lancet Respiratory Medicine. Researchers associated benzodiazepine infusions, invasive mechanical ventilation, antipsychotics, continuous opioid infusions, vasopressors and restraints with higher next-day delirium risk, while family interactions curbed odds of delirium.
Acute brain dysfunction in COVID-19 ICU patients examined
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.